Your browser doesn't support javascript.
loading
Comparison of half- and standard-dose ticagrelor in Chinese patients with NSTE-ACS.
Xue, H J; Shi, J; Liu, B; Wang, D Y; Dong, Z X; Guo, H; Kong, Y H; Sheng, L; Shao, Q; Sun, D H; Zhang, L; Pan, Y J; Dong, X W; Li, J Q; Xue, J Y; Zhou, Y Y; Yang, H P; Li, Y.
Afiliación
  • Xue HJ; a Cardiovascular Department , The First Clinical Hospital, Harbin Medical University , Harbin , P. R . China.
  • Shi J; a Cardiovascular Department , The First Clinical Hospital, Harbin Medical University , Harbin , P. R . China.
  • Liu B; a Cardiovascular Department , The First Clinical Hospital, Harbin Medical University , Harbin , P. R . China.
  • Wang DY; a Cardiovascular Department , The First Clinical Hospital, Harbin Medical University , Harbin , P. R . China.
  • Dong ZX; a Cardiovascular Department , The First Clinical Hospital, Harbin Medical University , Harbin , P. R . China.
  • Guo H; a Cardiovascular Department , The First Clinical Hospital, Harbin Medical University , Harbin , P. R . China.
  • Kong YH; a Cardiovascular Department , The First Clinical Hospital, Harbin Medical University , Harbin , P. R . China.
  • Sheng L; a Cardiovascular Department , The First Clinical Hospital, Harbin Medical University , Harbin , P. R . China.
  • Shao Q; a Cardiovascular Department , The First Clinical Hospital, Harbin Medical University , Harbin , P. R . China.
  • Sun DH; a Cardiovascular Department , The First Clinical Hospital, Harbin Medical University , Harbin , P. R . China.
  • Zhang L; a Cardiovascular Department , The First Clinical Hospital, Harbin Medical University , Harbin , P. R . China.
  • Pan YJ; a Cardiovascular Department , The First Clinical Hospital, Harbin Medical University , Harbin , P. R . China.
  • Dong XW; a Cardiovascular Department , The First Clinical Hospital, Harbin Medical University , Harbin , P. R . China.
  • Li JQ; a Cardiovascular Department , The First Clinical Hospital, Harbin Medical University , Harbin , P. R . China.
  • Xue JY; a Cardiovascular Department , The First Clinical Hospital, Harbin Medical University , Harbin , P. R . China.
  • Zhou YY; a Cardiovascular Department , The First Clinical Hospital, Harbin Medical University , Harbin , P. R . China.
  • Yang HP; a Cardiovascular Department , The First Clinical Hospital, Harbin Medical University , Harbin , P. R . China.
  • Li Y; a Cardiovascular Department , The First Clinical Hospital, Harbin Medical University , Harbin , P. R . China.
Platelets ; 27(5): 440-5, 2016 Jul.
Article en En | MEDLINE | ID: mdl-26830862
Ticagrelor is a novel direct-acting P2Y12 receptor antagonist used for preventing atherothrombotic events in patients with acute coronary syndromes (ACS). The current recommended dose is 90 mg bid, but a low dose of ticagrelor has not been previously studied in Chinese ACS patients. Therefore, we performed this study to observe the different effects of half- and standard-dose ticagrelor on platelet aggregation in Chinese patients with NSTE-ACS. Sixty-two NSTE-ACS subjects were assigned to half-dose ticagrelor (n = 20), standard-dose ticagrelor (n = 22) and clopidogrel (n = 20) groups. Five days after drug administration, VerifyNow P2Y12 assay was performed to test P2Y12 reaction units (PRU) and inhibition of platelet aggregation (IPA). High-platelet reactivity (HPR) was defined as a PRU > 208. The adverse events, including bleeding events and dyspnoea, were monitored throughout the study. PRU values in the half-dose (44.55 ± 32.88) and standard-dose (39.10 ± 40.02) ticagrelor were dramatically lower than those in the clopidogrel group (189.20 ± 65.22; P < 0.0001). The half-dose (84% ± 10%) and standard-dose (86% ± 13%) ticagrelor both showed greater IPA than clopidogrel (33% ± 20%; P < 0.0001). There were no significant differences in PRU and IPA between the two ticagrelor groups (P = 0.3085 and 0.4028, respectively). HPR rates were significantly lower in the two ticagrelor groups (0% for both) than those in the clopidogrel group (35%). In conclusion, half-dose ticagrelor had a similar inhibitory effect on platelet aggregation as standard-dose ticagrelor in Chinese patients with NSTE-ACS, which was significantly stronger than that of clopidogrel.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inhibidores de Agregación Plaquetaria / Adenosina / Síndrome Coronario Agudo / Antagonistas del Receptor Purinérgico P2Y Tipo de estudio: Diagnostic_studies / Etiology_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Platelets Asunto de la revista: HEMATOLOGIA Año: 2016 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inhibidores de Agregación Plaquetaria / Adenosina / Síndrome Coronario Agudo / Antagonistas del Receptor Purinérgico P2Y Tipo de estudio: Diagnostic_studies / Etiology_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Platelets Asunto de la revista: HEMATOLOGIA Año: 2016 Tipo del documento: Article Pais de publicación: Reino Unido